Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatient, 18-70 years of age~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder~* Minimum score of 20 on Hamilton Rating Scale for Anxiety~Exclusion Criteria:~* Women who are pregnant or who will be breastfeeding during the study~* Patients with a history of:~  1. Any manic or hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic or mixed episode~ 2. Any depressive episode with psychotic or catatonic features~ 3. Panic disorder with or without agoraphobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Dose-matched placebo tablets, oral administration
- Vilazodone (Type: EXPERIMENTAL): Vilazodone tablets, oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).